Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Adjunctive rehabilitation approaches to oncology / / editor Andrea L. Cheville ; consulting editor Santos F. Martinez
| Adjunctive rehabilitation approaches to oncology / / editor Andrea L. Cheville ; consulting editor Santos F. Martinez |
| Pubbl/distr/stampa | Philadelphia, Pennsylvania : , : Elsevier, , 2017 |
| Descrizione fisica | 1 online resource (285 pages) |
| Disciplina | 616.9940072 |
| Collana | Physical Medicine and Rehabilitation Clinics of North America |
| Soggetto topico | Oncology - Research |
| ISBN | 0-323-49674-1 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910158992003321 |
| Philadelphia, Pennsylvania : , : Elsevier, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in cancer research . Volume 125 ABC transporters and cancer / / edited by John D. Schuetz, Toshihisa Ishikawa ; contributors Suresh V. Ambudkar [and thirty one others]
| Advances in cancer research . Volume 125 ABC transporters and cancer / / edited by John D. Schuetz, Toshihisa Ishikawa ; contributors Suresh V. Ambudkar [and thirty one others] |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | London, England : , : Academic Press, , 2015 |
| Descrizione fisica | 1 online resource (280 p.) |
| Disciplina | 616.9940072 |
| Soggetto topico |
Cancer - Research
Drug resistance in cancer cells Cancer - Chemotherapy |
| Soggetto genere / forma | Electronic books. |
| ISBN | 0-12-801361-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; ABC Transporters and Cancer; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition; 1. Introduction to Apical ABC Transporters; 2. Impact of Apical ABC Transporters on Intestinal Absorption of Oral Chemotherapeutic Drugs; 2.1. Apical ABC transporters affecting the oral bioavailability of taxanes; 2.1.1. ABCB1 and oral taxane availability; 2.1.2. ABCC2 and oral taxane availability; 2.1.3. ABCB1 inhibitors to improve taxane oral availability
2.1.4. Assessing CNS toxicity risks of using ABCB1 inhibitors to improve oral taxane availability2.1.5. Possible effects of ABCB1 inhibitors on enhancing taxane antitumor efficacy; 2.2. Apical ABC transporters in the oral bioavailability of rationally designed anticancer drugs; 2.2.1. Tyrosine kinase inhibitors; 2.2.2. PARP inhibitors; 2.2.3. Chemical inhibition of transporters to increase oral availability of rationally designed anticancer drugs; 2.2.4. Importance of the sensitivity and specificity of in vitro assays used to assess ABC transporter substrates 3. Impact of Apical ABC Transporters on Brain Disposition of Oral Chemotherapeutic Drugs3.1. Does the BBB matter in drug delivery to brain tumors?; 3.2. Apical efflux transporters in the BBB affecting brain accumulation of anticancer drugs; 3.2.1. Drugs affected mostly by Abcb1a but also by Abcg2 in their brain accumulation; 3.2.2. Drugs only affected by Abcb1a in their brain accumulation; 3.2.3. Drugs affected mostly by Abcg2 but also by Abcb1a in their brain accumulation; 3.2.4. Three different apical BBB ABC efflux transporters affect brain accumulation of some camptothecins 3.2.5. Models to explain the disproportionate effect of combined deficiency of Abcb1 and Abcg2 on brain accumulation of s...3.2.6. Why are many rationally designed anticancer drugs still ABCB1 and/or ABCG2 substrates?; 3.2.7. Limitations of knockout mouse models to study ABC transporter functions at the BBB; 3.2.8. Tissue and cellular context may affect the in vivo impact of apical ABC efflux transporters; 3.2.9. Use of chemical inhibitors to enhance brain accumulation of ABC transporter substrate drugs; 4. Concluding Remarks; References Chapter 2: Regulation of ABC Transporters Blood-Brain Barrier: The Good, the Bad, and the Ugly1. Introduction; 2. Blood-Brain Barriers; 2.1. Assessing blood-brain barrier function; 3. ABC Transporters at the Blood-Brain Barrier; 4. The Bad and the Ugly: Mechanisms that Increase Transporter Expression and Reduce Drug Delivery to the CNS; 4.1. Xenobiotic-activated transcription factors; 4.2. Stress-activated transcription factors; 4.3. Disease; 5. The Good: Mechanisms that Reduce Transporter Activity/Expression and Have the Potential to Improve Drug Delivery to th...; 5.1. P-glycoprotein 5.2. BCRP |
| Record Nr. | UNINA-9910460672103321 |
| London, England : , : Academic Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in cancer research . Volume 125 ABC transporters and cancer / / edited by John D. Schuetz, Toshihisa Ishikawa ; contributors Suresh V. Ambudkar [and thirty one others]
| Advances in cancer research . Volume 125 ABC transporters and cancer / / edited by John D. Schuetz, Toshihisa Ishikawa ; contributors Suresh V. Ambudkar [and thirty one others] |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | London, England : , : Academic Press, , 2015 |
| Descrizione fisica | 1 online resource (280 p.) |
| Disciplina | 616.9940072 |
| Soggetto topico |
Cancer - Research
Drug resistance in cancer cells Cancer - Chemotherapy |
| ISBN | 0-12-801361-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; ABC Transporters and Cancer; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition; 1. Introduction to Apical ABC Transporters; 2. Impact of Apical ABC Transporters on Intestinal Absorption of Oral Chemotherapeutic Drugs; 2.1. Apical ABC transporters affecting the oral bioavailability of taxanes; 2.1.1. ABCB1 and oral taxane availability; 2.1.2. ABCC2 and oral taxane availability; 2.1.3. ABCB1 inhibitors to improve taxane oral availability
2.1.4. Assessing CNS toxicity risks of using ABCB1 inhibitors to improve oral taxane availability2.1.5. Possible effects of ABCB1 inhibitors on enhancing taxane antitumor efficacy; 2.2. Apical ABC transporters in the oral bioavailability of rationally designed anticancer drugs; 2.2.1. Tyrosine kinase inhibitors; 2.2.2. PARP inhibitors; 2.2.3. Chemical inhibition of transporters to increase oral availability of rationally designed anticancer drugs; 2.2.4. Importance of the sensitivity and specificity of in vitro assays used to assess ABC transporter substrates 3. Impact of Apical ABC Transporters on Brain Disposition of Oral Chemotherapeutic Drugs3.1. Does the BBB matter in drug delivery to brain tumors?; 3.2. Apical efflux transporters in the BBB affecting brain accumulation of anticancer drugs; 3.2.1. Drugs affected mostly by Abcb1a but also by Abcg2 in their brain accumulation; 3.2.2. Drugs only affected by Abcb1a in their brain accumulation; 3.2.3. Drugs affected mostly by Abcg2 but also by Abcb1a in their brain accumulation; 3.2.4. Three different apical BBB ABC efflux transporters affect brain accumulation of some camptothecins 3.2.5. Models to explain the disproportionate effect of combined deficiency of Abcb1 and Abcg2 on brain accumulation of s...3.2.6. Why are many rationally designed anticancer drugs still ABCB1 and/or ABCG2 substrates?; 3.2.7. Limitations of knockout mouse models to study ABC transporter functions at the BBB; 3.2.8. Tissue and cellular context may affect the in vivo impact of apical ABC efflux transporters; 3.2.9. Use of chemical inhibitors to enhance brain accumulation of ABC transporter substrate drugs; 4. Concluding Remarks; References Chapter 2: Regulation of ABC Transporters Blood-Brain Barrier: The Good, the Bad, and the Ugly1. Introduction; 2. Blood-Brain Barriers; 2.1. Assessing blood-brain barrier function; 3. ABC Transporters at the Blood-Brain Barrier; 4. The Bad and the Ugly: Mechanisms that Increase Transporter Expression and Reduce Drug Delivery to the CNS; 4.1. Xenobiotic-activated transcription factors; 4.2. Stress-activated transcription factors; 4.3. Disease; 5. The Good: Mechanisms that Reduce Transporter Activity/Expression and Have the Potential to Improve Drug Delivery to th...; 5.1. P-glycoprotein 5.2. BCRP |
| Record Nr. | UNINA-9910787425603321 |
| London, England : , : Academic Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in cancer research . Volume 125 ABC transporters and cancer / / edited by John D. Schuetz, Toshihisa Ishikawa ; contributors Suresh V. Ambudkar [and thirty one others]
| Advances in cancer research . Volume 125 ABC transporters and cancer / / edited by John D. Schuetz, Toshihisa Ishikawa ; contributors Suresh V. Ambudkar [and thirty one others] |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | London, England : , : Academic Press, , 2015 |
| Descrizione fisica | 1 online resource (280 p.) |
| Disciplina | 616.9940072 |
| Soggetto topico |
Cancer - Research
Drug resistance in cancer cells Cancer - Chemotherapy |
| ISBN | 0-12-801361-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; ABC Transporters and Cancer; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition; 1. Introduction to Apical ABC Transporters; 2. Impact of Apical ABC Transporters on Intestinal Absorption of Oral Chemotherapeutic Drugs; 2.1. Apical ABC transporters affecting the oral bioavailability of taxanes; 2.1.1. ABCB1 and oral taxane availability; 2.1.2. ABCC2 and oral taxane availability; 2.1.3. ABCB1 inhibitors to improve taxane oral availability
2.1.4. Assessing CNS toxicity risks of using ABCB1 inhibitors to improve oral taxane availability2.1.5. Possible effects of ABCB1 inhibitors on enhancing taxane antitumor efficacy; 2.2. Apical ABC transporters in the oral bioavailability of rationally designed anticancer drugs; 2.2.1. Tyrosine kinase inhibitors; 2.2.2. PARP inhibitors; 2.2.3. Chemical inhibition of transporters to increase oral availability of rationally designed anticancer drugs; 2.2.4. Importance of the sensitivity and specificity of in vitro assays used to assess ABC transporter substrates 3. Impact of Apical ABC Transporters on Brain Disposition of Oral Chemotherapeutic Drugs3.1. Does the BBB matter in drug delivery to brain tumors?; 3.2. Apical efflux transporters in the BBB affecting brain accumulation of anticancer drugs; 3.2.1. Drugs affected mostly by Abcb1a but also by Abcg2 in their brain accumulation; 3.2.2. Drugs only affected by Abcb1a in their brain accumulation; 3.2.3. Drugs affected mostly by Abcg2 but also by Abcb1a in their brain accumulation; 3.2.4. Three different apical BBB ABC efflux transporters affect brain accumulation of some camptothecins 3.2.5. Models to explain the disproportionate effect of combined deficiency of Abcb1 and Abcg2 on brain accumulation of s...3.2.6. Why are many rationally designed anticancer drugs still ABCB1 and/or ABCG2 substrates?; 3.2.7. Limitations of knockout mouse models to study ABC transporter functions at the BBB; 3.2.8. Tissue and cellular context may affect the in vivo impact of apical ABC efflux transporters; 3.2.9. Use of chemical inhibitors to enhance brain accumulation of ABC transporter substrate drugs; 4. Concluding Remarks; References Chapter 2: Regulation of ABC Transporters Blood-Brain Barrier: The Good, the Bad, and the Ugly1. Introduction; 2. Blood-Brain Barriers; 2.1. Assessing blood-brain barrier function; 3. ABC Transporters at the Blood-Brain Barrier; 4. The Bad and the Ugly: Mechanisms that Increase Transporter Expression and Reduce Drug Delivery to the CNS; 4.1. Xenobiotic-activated transcription factors; 4.2. Stress-activated transcription factors; 4.3. Disease; 5. The Good: Mechanisms that Reduce Transporter Activity/Expression and Have the Potential to Improve Drug Delivery to th...; 5.1. P-glycoprotein 5.2. BCRP |
| Record Nr. | UNINA-9910811415603321 |
| London, England : , : Academic Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Anticancer Plants: Natural Products and Biotechnological Implements [[electronic resource] ] : Volume 2 / / edited by Mohd Sayeed Akhtar, Mallappa Kumara Swamy
| Anticancer Plants: Natural Products and Biotechnological Implements [[electronic resource] ] : Volume 2 / / edited by Mohd Sayeed Akhtar, Mallappa Kumara Swamy |
| Edizione | [1st ed. 2018.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2018 |
| Descrizione fisica | 1 online resource (XV, 564 p. 139 illus., 21 illus. in color.) |
| Disciplina | 616.9940072 |
| Soggetto topico |
Plant physiology
Agriculture Proteins Plant genetics Cancer Plant Physiology Protein Biochemistry Plant Genetics Cancer Biology |
| ISBN | 981-10-8064-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Fungal Endophytes as Novel Sources of Anticancer Compounds -- Chapter 2. Gastrointestinal Bezoar Stones: Current Knowledge and Future Pperspective on the Potential of Plant-derived Phytobezoar in Cancer Treatment -- Chapter 3. Potential of Natural Products for Prevention of Oral Cancer -- Chapter 4. Therapeutic Potential of Cardiac Glycosides Against Cancer -- Chapter 5. Conserving Biodiversity of a Potent Anticancer Plant, Catharanthus roseus Through In vitro Biotechnological Intercessions: Substantial Progress and Imminent Prospects -- Chapter 6. Medicinal Plants as a Potential Source of Chemopreventive Agents -- Chapter 7. Plant Metabolites as New Leads to Anticancer Drug Discovery: Approaches and Challenges -- Chapter 8. Terpenes of Genus Salvia: Cytotoxicity and Antitumoral Effects -- Chapter 9. Essential Oil with Anticancer Activity: An Overview -- Chapter 10. Fungal Endophytes from Anticancer Plants as Producers of the Anti-tumour Agent L-Asparaginase: A Look at Diversity, Ubiquity and Enzyme Production -- Chapter 11. Xylooligosaccharides and their Anticancer Potential: An Update -- Chapter 12. Phytochemicals Targeting Endoplasmic Reticulum Stress to Inhibit Cancer Cell Proliferation -- Chapter 13. Remedy of Targeting Cancer andCcancer Stem Cells with Botanicals -- Chapter 14. Therapeutic Strategies of Natural Agents and its Components on Triple-Negative Breast Cancer -- Chapter 15. Endophytic Microbes as a Novel Source for Producing Anticancer Compounds as Multidrug Resistance Modulators. Chapter 16. Traditional Medicinal Plants and their Therapeutic Potential Against Major Cancer Types -- Chapter 17. Platelet Derived Growth Factor Receptor (PDGF-R) as the Target for Herbal Based Anticancer Agents -- Chapter 18. Plant Cell and Organ Culture as an Alternative for the Production of Anticancer Compounds -- Chapter 19. Plant Derived Extracts and Compounds: An Alternative Therapy Against Breast Cancer -- Chapter 20. Micropropagation and Conservation of Selected Endangered Anticancer Medicinal Plants from the Western Ghats of India -- Chapter 21. Biotechnological Approaches for the Propagation of Anticancer Plants and the Production of Vital Compounds -- Chapter 22. An Alternative Approach for Anticancer Compounds Production Through Plant Tissue Culture Techniques -- Chapter 23. Biotechnological Intervention Through Tissue Culture in Hedychium coronarium: A Potential Anticancer Plant. . |
| Record Nr. | UNINA-9910298396303321 |
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Autophagy in tumor and tumor microenvironment / / Sujit Kumar Bhutia, editor
| Autophagy in tumor and tumor microenvironment / / Sujit Kumar Bhutia, editor |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2020] |
| Descrizione fisica | 1 online resource (VII, 280 p. 38 illus., 37 illus. in color.) |
| Disciplina | 616.9940072 |
| Soggetto topico |
Cancer - Research
Immunology Drug resistance |
| ISBN | 981-15-6930-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Role of xenobiotic in autophagy inflection in cell death and carcinogenesis -- Chapter 2. Autophagy – An agonist and antagonist with an interlink of apoptosis in cancer -- Chapter 3. Cross-talk between DNA damage and autophagy and its implication in cancer therapy -- Chapter 4. miRNAs and its regulatory role on autophagy in tumor microenvironment -- Chapter 5. Exploring the metabolic implications of autophagy modulation in tumor microenvironment -- Chapter 6. Mitophagy and Reverse Warburg Effect: Metabolic Compartmentalization of Tumor Microenvironment -- Chapter 7. Mitochondrial Biogenesis, Mitophagy, and Mitophagic cell death in Cancer Regulation: A Comprehensive Review -- Chapter 8. Mechanical stress-induced autophagy: a key player in cancer metastasis -- Chapter 9. The Interplay of Autophagy and the Immune system in the Tumor Microenvironment -- Chapter 10. Relevance of autophagy in cancer stem cell and therapeutic -- Chapter 11. The Autophagy Conundrum in Cancer Development, Progression and Therapeutics -- Chapter 12. Targeting Autophagy in Cancer: Therapeutic implications -- Chapter 13. Mechanistic insights into Autophagosome-Lysosome Fusion in Cancer Therapeutics. |
| Record Nr. | UNINA-9910424638003321 |
| Singapore : , : Springer, , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biomarkers in Kidney Disease [[electronic resource] /] / edited by Vinood B. Patel, Victor R. Preedy
| Biomarkers in Kidney Disease [[electronic resource] /] / edited by Vinood B. Patel, Victor R. Preedy |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2016 |
| Descrizione fisica | 1 online resource (208 illus., 150 illus. in color. eReference.) |
| Disciplina | 616.9940072 |
| Collana | Biomarkers in Disease: Methods, Discoveries and Applications |
| Soggetto topico |
Cancer research
Oncology Pharmacology Cancer Research Oncology Pharmacology/Toxicology |
| ISBN | 94-007-7699-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Volume Preface -- Series Preface -- Contents -- About the Editors -- Editorial Advisors -- Contributors -- Part I: General Aspects -- 1 Biomarkers in Kidney Transplantation -- Key Facts -- Key Facts of Operational Tolerance -- Key Facts of Costimulatory Signal -- Definitions -- Introduction -- Biomarkers of Allograft Rejection -- Urine Biomarkers -- Perforin, Granzyme B, and Fas-L mRNA -- Granzyme A mRNA -- Foxp3 mRNA -- Cytokine/Chemokine mRNA -- OX40/OX40-L mRNA -- mRNA Signature -- Urine miRNAs -- Urine Proteomics -- Blood Biomarkers -- CD30 -- Genomics -- miRNAs -- Biomarkers of -- Gene Expression Studies -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 2 Diagnostic Biomarkers of Acute Kidney Injury in Newborns -- Key Facts of Diagnostic Biomarkers of Acute Kidney Injury in Newborns -- Definitions -- Introduction -- Biomarkers of Acute Kidney Injury -- Cystatin C -- Neutrophil Gelatinase-Associated Lipocalin -- Interleukin-18 -- Kidney Injury Molecule-1 -- Fibroblast Growth Factor-2 -- Urinary Epidermal Growth Factor -- Urine Metabolomic Profiling -- Discussion -- Conclusions -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 3 Osmolal Gap as a Biomarker in Kidney Injury: Focusing on the Differential Diagnosis of Metabolic Acidosis -- Key Facts of the Osmolal Gap -- Definitions -- Introduction -- Definition -- Estimation of the Osmolal Gap -- Measured Osmolality -- Calculation of Osmolality -- Calculated Serum Osmolality -- Calculated Urine Osmolality -- Serum or Urine Osmolal Gap -- Clinical Utility of the Serum and Urine Osmolal Gap -- Serum Osmolal Gap -- Urine Osmolal Gap -- Limitations to the Clinical Utility of the Osmolal Gap -- Various Causes of an Osmolal Gap -- Limitations of Methods of Osmometry -- Summary Points.
References -- 4 Peritoneal Effluent Biomarker Discovery in Peritoneal Dialysis: The Omics Era -- Definitions -- Introduction -- Methodological Considerations -- Analytical Validity -- Study Designs and Population -- Omics Data Analysis -- Current Developments -- Proteomics -- Genomics and Metabolomics -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Future Directions -- Summary Points -- References -- 5 Metabolomics and Stages of Chronic Kidney Disease -- Key Facts About Metabolomics and Stages of Chronic Kidney Disease -- Definitions -- Introduction -- Why Use Metabolomics to Diagnose CKD -- Using Mass Spectrometry for Metabolite Exploration -- Nontarget Analysis and Target Analysis -- Nontarget Analysis -- Target Analysis (Multi-target Analysis) -- Future of Metabolomics in the Diagnosis of Disease -- Potential Applications to Prognosis and Other Diseases and Conditions -- Summary Points -- References -- 6 Hypoxia as a Biomarker of Kidney Disease -- Key Facts of Kidney Oxygenation -- Definitions -- Introduction -- Chronic Kidney Disease -- The Role of Hypoxia in the Pathogenesis of Chronic Kidney Disease -- The Clinical Problem: Early Diagnosis and Instigation of Therapy -- Assessment of Kidney Oxygenation by BOLD MRI in Chronic Kidney Disease -- Acute Kidney Injury -- The Role of Hypoxia in the Pathogenesis of Acute Kidney Injury -- The Clinical Problem: Prevention of Acute Kidney Injury in the Hospital Setting -- Cardiac Surgery -- Sepsis -- Radiocontrast Agents and Other Nephrotoxins -- Urinary PO2 as a Diagnostic Biomarker in Acute Kidney Injury -- Potential Applications to Prognosis, Other Disease and Conditions -- Summary Points -- References -- 7 MicroRNAs in Kidney Diseases -- Key Facts -- Key Facts of Renal Physiology -- Key Facts of PKD -- Key Facts of Primary and Secondary Glomerulonephritis. Key Facts of Kidney Transplantation -- Key Facts of miRNA Therapy -- Definitions -- Introduction: Biogenesis of miRNAs -- New Strategies for Detection of Renal miRNA -- MiRNAs in Renal Physiology -- Blood Flow and Oxygen Supply -- Glomerular Filtration -- Tubular Reabsorption and Excretion -- Interstitial Osmolarity -- MiRNAs in Polycystic Kidney Disease -- MiRNAs in Primary and Secondary Glomerulonephritis -- MiRNAs in Kidney Transplantation -- Potential Applications to Prognosis and Other Diseases or Conditions -- MiRNAs as Diagnostic Tools in Blood and Urine -- New Approaches for miRNA Therapy -- Therapeutic Approaches -- MiRNAs as Potential Therapeutic Strategies -- Challenges and Future Perspectives -- Summary Points -- References -- 8 Serum Creatinine Trajectories in Kidney Disease -- Key Facts -- Definitions -- Introduction -- Creatinine: Metabolism, Chemical Structure, and Excretion in the Urine -- Serum Creatinine Trajectories in Kidney Disease -- Serum Creatinine Trajectories in Acute Kidney Injury (AKI): The Rainbow Spectrum of Renal Outcomes Following AKI in CKD Patien... -- Rapid and Full Recovery of Renal Function Following AKI on CKD -- Partial Recovery of Renal Function Following AKI on CKD -- Rapid-Onset Yet Irreversible ESRD or the Syndrome of Rapid-Onset ESRD (SORO-ESRD) Following AKI on CKD in a Patient with Nativ... -- Rapid-Onset Yet Irreversible ESRD or the Syndrome of Rapid-Onset ESRD (SORO-ESRD) Following AKI on CKD in a Renal Transplant R... -- Serum Creatinine Trajectories in Adult Polycystic Kidney Disease (ADPKD): An Nnamdi Azikiwe University Teaching Hospital, New... -- Case I -- Case II -- Serum Creatinine Trajectories in Chronic Kidney Disease: The NKF KDOQI CKD Staging Paradigm Revisited: CKD Prediction Is an In... -- Stable CKD V Over 7Years in a Now 78-Year-Old Caucasian Hypertensive Diabetic Male. Stable CKD IV Over 8Years in a Now 78-Year-Old Caucasian Hypertensive Diabetic Male -- Stable CKD III Over Nearly 10Years in a Now 87-Year-Old Caucasian Hypertensive Male -- Two Divergent Patterns of CKD to ESRD Progression: The ``Classic´´ Pattern and the Pattern of the Syndrome of Rapid-Onset End-... -- ``Classic´´ Pattern of CKD-ESRD Progression in a Hypertensive Caucasian Male -- ``Classic´´ Pattern of CKD-ESRD Progression in a Caucasian Hypertensive Diabetic Male -- Pattern of Syndrome of Rapid-Onset ESRD in a Caucasian Hypertensive Diabetic Male -- Late-Onset End-Stage Renal Failure from Angiotensin Blockade (LORFFAB) -- Serum Creatinine Trajectories in a Case of ``Quadruple Whammy´´ -- Perioperative AKI and Concurrent Angiotensin Inhibition Alone: A Case Presentation from Mayo Clinic Health System, Eau Claire,... -- Serum Creatinine Trajectories in HIV-Associated Nephropathy: An Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria, R... -- Case I -- Case II -- Serum Creatinine Trajectories in Sickle Cell Disease Nephropathy: An Nnamdi Azikiwe University Teaching Hospital, Nnewi, Niger... -- Conclusions: A Need for More Preventative Renal Medicine: Renoprevention Revisited. The Introduction of the New Innovative CKD... -- Potential Applications of Serum Creatinine Trajectories in Kidney Disease Prognostication and Management -- Summary Points -- References -- 9 Random Spot Urine Markers for Kidney and Their Applications -- Key Facts of Urinalysis -- Definitions -- Introduction -- The Specimen for Analysis -- Physical Markers -- Color -- Odor -- Turbidity or Clarity -- Relative Density -- Chemical Markers -- Blood -- pH -- Bilirubin -- Urobilinogen -- Ketones -- Nitrites and Leukocyte Esterase -- Glucose -- Albuminuria -- Protein -- Uric Acid -- Electrolytes -- Sodium -- Potassium -- Phosphate -- Others -- Microscopic Markers. Erythrocytes -- Leukocytes -- Cells -- Lipids -- Casts -- Crystals -- Organisms -- Conclusions -- Potential Applications to Prognosis, Other Diseases, or Conditions -- Summary Points -- References -- 10 Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology -- Key Facts of Creatinine -- Definitions -- Introduction -- NGAL and Acute Kidney Injury -- NGAL and Autosomal-Dominant Polycystic Kidney Disease (ADPKD) -- NGAL and Chronic Kidney Disease -- NGAL in Kidney Transplant Patients -- Potential Applications to Prognosis and Other Diseases or Conditions -- Summary Points -- References -- 11 Chemokines as Potential Markers in Pediatric Renal Diseases -- Key Facts of Chemokines in Pediatric Renal Disease -- Definitions -- Chemokines: General Concepts -- Chemokines in Renal Diseases -- Chemokines in Glomerular Diseases -- Chemokines in Congenital Uropathies -- Ureteropelvic Junction Obstruction -- Vesicoureteral Reflux -- Potential Applications to Prognosis, Other Diseases or Conditions -- Summary Points -- References -- 12 Kidney and Neoplastic Disease: Overview with a Particular Interest to Interpretation of Cancer Biomarkers -- Key Facts of Renal Disease Subsequent to Neoplasia -- Key Facts of Neoplasia Risk in Renal Patients -- Key Facts of Neoplasia Risk in Renal Patients -- Definitions -- Introduction -- Renal Disease Associated with Malignancies -- Malignancy Associated with Renal Disease -- Breast Cancer -- Colorectal Cancer -- Women-Specific Tumoral Diseases: Cervical Cancer and Ovary Cancer -- Lung Cancer -- Liver Cancer -- Prostate Cancer -- Tumors of the Urinary Tract: Kidney, Ureters, and Bladder -- Markers of Cancer and Renal Function -- Conclusions -- Summary Points -- References -- Part II: Circulating and Body Fluid Biomarkers -- 13 Creatinine Assays in Early Infancy: How to Aim for a Moving Target. Key Facts of Creatinine Assays and Their Clinical Relevance in Early Infancy. |
| Record Nr. | UNINA-9910253896203321 |
| Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer nanotheranostics . Volume 2 / / Muthupandian Saravanan, Hamed Barabadi
| Cancer nanotheranostics . Volume 2 / / Muthupandian Saravanan, Hamed Barabadi |
| Autore | Saravanan Muthupandian |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer International Publishing, , [2021] |
| Descrizione fisica | 1 online resource (379 pages) : illustrations |
| Disciplina | 616.9940072 |
| Collana | Nanotechnology in the Life Sciences |
| Soggetto topico |
Cancer - Research
Biotechnology Theranostic Nanomedicine Neoplasms - therapy Nanoparticles Càncer |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-76263-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910502646403321 |
Saravanan Muthupandian
|
||
| Cham, Switzerland : , : Springer International Publishing, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer Research: An Interdisciplinary Approach [[electronic resource] /] / edited by Nima Rezaei
| Cancer Research: An Interdisciplinary Approach [[electronic resource] /] / edited by Nima Rezaei |
| Autore | Rezaei Nima |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (614 pages) |
| Disciplina | 616.9940072 |
| Collana | Interdisciplinary Cancer Research |
| Soggetto topico |
Cancer
Cancer—Treatment Stem cells Cytology Medical genetics Immunology Cancer Biology Cancer Therapy Cancer Stem Cells Cell Biology Medical Genetics |
| ISBN | 3-031-32458-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Interdisciplinary Approaches in Cancer Research -- Role of Immune Cells in the Tumor Microenvironment -- Spatial Transcriptomic Approaches for Understanding the Tumor Microenvironment (TME) -- Role of Mesenchymal Stem/Stromal Cells in Cancer Development -- Cancer-associated Fibroblasts and Their Role in Cancer Progression -- The Role of Tumoroids in Cancer Research -- Myokines Expression in Cancer Cachexia -- Epigenetics in Cancer Biology -- Epigenetic Regulation of Cancer by Natural Touch: Phytochemicals and Epigenetic Regulation -- Telomerase Reverse Transcriptase in Humans: From Biology to Cancer Immunity -- Molecular Mechanisms of Metal-induced Carcinogenesis -- Epi-drugs Targeting RNA Dynamics in Cancer -- Oncologic Emergencies: Pathophysiology, Diagnosis, and Initial Management -- Malignancies in Inborn Errors of Immunity -- Hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity and Malignancy -- Personalized Immuno-oncology with Immunodeficiency Mouse Models -- Allergy and Cancer: New Perspectives -- Depression and Cancer: the Inflammatory Bridge -- Impact of Cancer-Related Sarcopenia on Systemic Immune Status -- Surveillance of Subclinical Cardiovascular Complications in Childhood Cancer Survivors: Exercise as a Diagnostic and Therapeutic Modality. |
| Record Nr. | UNINA-9910734848103321 |
|
Rezaei Nima
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer stem cells : new horizons in cancer therapies / / Surajit Pathak, Antara Banerjee, editors
| Cancer stem cells : new horizons in cancer therapies / / Surajit Pathak, Antara Banerjee, editors |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2020] |
| Descrizione fisica | 1 online resource (VII, 369 p. 65 illus., 58 illus. in color.) |
| Disciplina | 616.9940072 |
| Soggetto topico |
Cancer - Research
Cancer - Treatment - Technological innovations |
| ISBN | 981-15-5120-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Introduction to cancer stem cells -- Chapter 2. Types of Cancer Stem Cells -- Chapter 3. Isolation and Characterization of Cancer Stem Cells (CSCs) -- Chapter 4. Lung and Prostate Cancer Stem Cells -- Chapter 5. A differential role of miRNAs in regulation of breast cancer stem cells -- Chapter 6. Skin stem cells in cancer -- Chapter 7. Ocular Cancer stem cells: Advances in therapeutic interventions -- Chapter 8. Cancer Stem Cells and Tumour Aggressiveness -- Chapter 9. Therapeutic Implication of Cancer Stem Cells.-Chapter 10. Glioblastoma stem cells as a therapeutic target -- Chapter 11. Cancer stem cells and therapeutic angiogenesis -- Chapter 12. Cancer stem cells as a seed for cancer metastasis -- Chapter 13. Functionality of intron specific genes and cancer stem cells in the progression of colorectal cancer -- Chapter 14. Technological advancement in Cancer Stem Cell Research -- Chapter 15. Controversies in Isolation and Characterization of Cancer Stem Cells -- Chapter 16. Targeting therapies for cancer stem cells -- Chapter 17. Targeting Cancer stem cells by nanoenabled drug delivery -- Chapter 18. Cancer Stem Cells in Patients Survival and Therapies in Cancer.-. |
| Record Nr. | UNINA-9910424639503321 |
| Singapore : , : Springer, , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
